Results 251 to 260 of about 2,156,166 (288)
Some of the next articles are maybe not open access.
THERAPEUTIC MONOCLONAL ANTIBODIES
Rheumatology, 1995Monoclonal antibodies have been used extensively over the last few years in clinical trials of rheumatoid arthritis (RA). Not only are they potential therapeutic agents, but they are also useful probes into the immunopathogenesis of RA. Anti-tumour necrosis factor alpha (TNF alpha) monoclonal antibodies have been shown to be clinically efficacious ...
E H, Choy, G S, Panayi, G H, Kingsley
openaire +2 more sources
2001
Publisher Summary Monoclonal antibody therapy (MAT) makes use of all the major features of the immune response. It involves vaccination/ immunization, albeit in experimental animals, to induce the desired specific immune response. It exploits the high specificity, selectivity, and affinity of the antibody complementarity-determining regions (CDRs ...
J W, Park, J, Smolen
openaire +2 more sources
Publisher Summary Monoclonal antibody therapy (MAT) makes use of all the major features of the immune response. It involves vaccination/ immunization, albeit in experimental animals, to induce the desired specific immune response. It exploits the high specificity, selectivity, and affinity of the antibody complementarity-determining regions (CDRs ...
J W, Park, J, Smolen
openaire +2 more sources
Current Opinion in Cardiology, 1996
Monoclonal antibody technology has become an important diagnostic and therapeutic tool in many areas of medicine, including the prevention and treatment of organ transplant rejection. The monoclonal antibody that has been most widely used clinically is OKT3, a murine monoclonal antibody directed against the CD3 receptor on the surface of human T cells.
openaire +2 more sources
Monoclonal antibody technology has become an important diagnostic and therapeutic tool in many areas of medicine, including the prevention and treatment of organ transplant rejection. The monoclonal antibody that has been most widely used clinically is OKT3, a murine monoclonal antibody directed against the CD3 receptor on the surface of human T cells.
openaire +2 more sources
Monoclonal antibody biosimilars
Nature Reviews Drug Discovery, 2015With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics.
Natasha, Udpa, Ryan P, Million
openaire +2 more sources
Radiolabeled Monoclonal Antibodies
AORN Journal, 1995ABSTRACTMonoclonal antibodies (MoAbs) are biologically engineered proteins designed to bind to antigens emanating from tumor cells. Selected radioactive isotopes are fused with MoAbs to allow radioimmunodetection or external imaging of metastatic deposits in patients with colon cancer.
C L, Brumley, J A, Kuhn
openaire +2 more sources
2009
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
The ability to produce and exploit monoclonal antibodies (mAbs) has revolutionized many areas of biological sciences. The unique property of an mAb is that it is a single species of immunoglobulin (IG) molecule. This means that the specificity of the interaction of the paratopes on the IG, with the epitopes on an antigenic target, is the same on every ...
openaire +2 more sources
Monoclonal antibody technology
American Journal of Health-System Pharmacy, 1986The development, production, limitations, and uses of monoclonal antibody (MoAb) technology are presented. The first MoAbs were developed in 1975 using a process whereby the antibody-producing spleen cells of mice that had been immunized against sheep red blood cells were fused with the cells of a mouse myeloma cell line, producing hybridomas.
J A, Tami +3 more
openaire +2 more sources
Drug News & Perspectives, 2005
The success of molecular target-based cancer therapy exampled by Herceptin targeting Her2 indicates that cancer immunotherapy involves identifying and targeting key molecular drivers of cancer. Recently, the human Cripto, a founding member of the epidermal growth factor-Cripto-FRL1-Cryptic (EGF-CFC) protein family has been demonstrated to be a unique ...
Xiu Feng, Hu, Pei Xiang, Xing
openaire +2 more sources
The success of molecular target-based cancer therapy exampled by Herceptin targeting Her2 indicates that cancer immunotherapy involves identifying and targeting key molecular drivers of cancer. Recently, the human Cripto, a founding member of the epidermal growth factor-Cripto-FRL1-Cryptic (EGF-CFC) protein family has been demonstrated to be a unique ...
Xiu Feng, Hu, Pei Xiang, Xing
openaire +2 more sources
Recombinant Monoclonal Antibodies
2007Recombinant antibody technology is a rapidly evolving field that enables the study and improvement of antibody properties by means of genetic engineering. Moreover, the functional expression of antibody fragments in Escherichia coli has formed the basis for antibody library generation and selection, a powerful method to produce human antibodies for ...
Mariel, Donzeau, Achim, Knappik
openaire +2 more sources
Therapeutic monoclonal antibodies
The Lancet, 2000The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully humanised mAb can now be made by recombinant engineering. About a quarter of all biotech drugs in development are mAb, and around 30 products are in use or being ...
openaire +2 more sources